Oncology Brothers: Practice-Changing Cancer Discussions Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
Jul 24, 2025
Dr. Anand Patel, a hematologist and medical director at the University of Chicago, joins the hosts to dive deep into acute myeloid leukemia (AML). He discusses the current standards for diagnosing and risk stratifying AML patients. The conversation highlights the significance of molecular profiling in tailoring treatment plans. They explore induction chemotherapy options, including the classic 7+3 regimen and innovative therapies like venetoclax for unfit patients. Finally, they touch on the promise of emerging targeted therapies aimed at improving patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Molecular Profiling Drives Strategy
- Broad molecular profiling guides immediate treatment intensity and long-term consolidation/transplant decisions.
- Use ELN22 for intensive chemo and ELN24 for lower-intensity therapy risk stratification.
Induction And Consolidation Choices
- Use 7+3 for fit patients and add gemtuzumab for core binding factor AML when appropriate.
- Add a FLT3 inhibitor if FLT3-mutated, and consolidate with cytarabine (1.5 g/m2 sufficient per recent evidence).
Plan For Transplant Early
- For intermediate/high-risk AML aim to induce remission and move eligible patients to allogeneic transplant.
- Patients usually receive at least one consolidation cycle before transplant rather than going directly to transplant.